About Somatuline Depot (lanreotide) Injection
For your patients with acromegaly, Somatuline® Depot (lanreotide) Injection is a simply effective way to go
The first acromegaly treatment available in a 28-day prefilled syringe, Somatuline® Depot (lanreotide) Injection is something for your patients.1,2
With Somatuline® Depot (lanreotide) Injection, you can offer your patients the freedom of a simple, deep subcutaneous injection.1 Find out more about how Somatuline® Depot (lanreotide) Injection is patient- and professional-friendly. And see how Somatuline® Depot (lanreotide) Injection is injected in a short video.
See if your patients would benefit from the powerful, long-term efficacy of Somatuline® Depot (lanreotide) Injection.1
Learn about the proven safety and tolerability of Somatuline® Depot (lanreotide) Injection, including a low discontinuation rate and a demonstrated cardiovascular profile.1,2
Look into a pharmacokinetic profile that may deliver efficacy in 24 hours through its selective binding to key somatostatin receptors.1,10
Discover the flexibility and convenience of three different Somatuline® Depot (lanreotide) Injection dosing strengths.1
Determine which of your patients are right for Somatuline® Depot (lanreotide) Injection by reading about three distinct types of patients with acromegaly.
Read more within the Full Prescribing Information.
Indication and Important Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.
There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.
A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).
For Full Prescribing Information, click here.
